Follow Healthline   |   Healthline on TwitterTwitter   |   Healthline on FacebookFacebook
Symptom Search   |   Treatment Search   |   Doctor Search   |   Drug Search

Drug Notebook

FDA Alerts

    Mortality
  • Excessive mortality or nonfatal cardiac arrest rate (7.7%) in encainide- or flecainide-treated patients with asymptomatic non-life-threatening ventricular arrhythmias (with MI history >6 days but <2 years) in NHLBI's long-term CAST study relative to placebo. (See Mortality under Cautions.)
  • Applicability of CAST findings to other populations (e.g., those without recent MI) uncertain.
  • Because of disopyramide's proarrhythmic properties and lack of evidence of improved survival for any antiarrhythmic drug, reserve disopyramide for life-threatening ventricular arrhythmias.

Media Gallery
Drug Info Tools
Search by color, shape and markings. click here
Check any 2 drugs for interactions. click here
Compare any two drugs side by side. click here
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
Advertisement
Marketplace
disopyramide
(dye soe PEER a mide)
ETHEX 002 | 150 mgETHEX 002   150 mg
bottle, 100 each Disopyramide PO4 150mg, Oral capsule, extended release, orange, purple, translucent, oblong-shaped, side 1:ETHEX 002
NORPACE CR 100mg SEARLE 2732 | 100 mgNORPACE CR 100mg SEARLE 2732   100 mg
bottle, 100 each Disopyramide PO4 100mg, Oral capsule, extended release, green, white, oblong-shaped, side 1:NORPACE CR 100mg SEARLE 2732
NORPACE CR 150mg SEARLE 2742 | 150 mgNORPACE CR 150mg SEARLE 2742   150 mg
bottle, 100 each Disopyramide PO4 150mg, Oral capsule, extended release, brown, green, oblong-shaped, side 1:NORPACE CR 150mg SEARLE 2742
Back to Top